# Nivestim® (Filgrastim) Tolerance in Patients Treated by Toxic Chemotherapeutic Agents

> **NCT01574235** · — · COMPLETED · sponsor: **Hospira, now a wholly owned subsidiary of Pfizer** · enrollment: 2114 (actual)

## Conditions studied

- Solid Tumors
- Malignant Hemopathy
- Chemotherapy-induced Febrile Neutropenia (FN)

## Interventions

- **BIOLOGICAL:** Nivestim®

## Key facts

- **NCT ID:** NCT01574235
- **Lead sponsor:** Hospira, now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10
- **Primary completion:** 2014-02
- **Final completion:** 2014-02
- **Target enrollment:** 2114 (ACTUAL)
- **Last updated:** 2015-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01574235

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01574235, "Nivestim® (Filgrastim) Tolerance in Patients Treated by Toxic Chemotherapeutic Agents". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01574235. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*